Japan Artificial Intelligence in Diagnostics Market Insight
Published: 06 June 2026 | Report Format: Electronic (PDF)
The Japan artificial intelligence in diagnostics market is projected to grow at a CAGR of 18.61% driven by an aging population, rising demand for early disease detection, shortages of radiologists and pathologists, government support for digital health, and increasing AI-powered diagnostic investments
Japan Artificial Intelligence in Diagnostics Market Insights Forecasts to 2035
- The Japan Artificial Intelligence in Diagnostics Market Size Was Estimated at USD 60.15 Million in 2024, representing approximately 4.5% of the global AI in diagnostics market
- The Market Size is Expected to Grow at a CAGR of around 18.61% from 2025 to 2035, driven by government-backed digital health initiatives, widespread hospital AI adoption, and rapid advances in machine learning algorithm accuracy
- The Japan Artificial Intelligence in Diagnostics Market Size is Expected to Rise to around USD 673.91 Million by 2035, underpinned by expanding AI integration across radiology, oncology, pathology, and cardiology diagnostic workflows nationwide
Notable Insights for the Japan Artificial Intelligence in Diagnostics Market
- Segmentation on the basis of Component indicates that the Software segment holds the dominant position in the Japan Artificial Intelligence in Diagnostics Market in 2025 with a significant revenue share, driven by widespread deployment of AI-powered diagnostic imaging software, deep learning platforms, and cloud-integrated clinical decision support systems across major hospitals and imaging centres in Japan.
- Segmentation on the basis of Diagnosis Type indicates that the Radiology & Medical Imaging application segment holds the dominant position in the Japan Artificial Intelligence in Diagnostics Market in 2025 with a market share of around 38% owing to high adoption of AI-driven CT, MRI, and X-ray analysis tools at institutions such as Fujita Health University Hospital and the National Cancer Center Hospital in Tokyo.
Download the eBook (ToC)
- FUJIFILM Holdings Corporation, a domestic market leader in AI-enabled diagnostics, launched its cloud-based SYNAPSE AI platform in April 2024 for the development of AI technologies in diagnostic imaging, reinforcing its dominant position across Japan’s radiology and oncology diagnostic segments.
- Japan’s aging population, projected to account for 36.5% of the total population by 2040, is a structural growth driver for AI diagnostics, significantly increasing the burden of chronic diseases such as cancer, diabetes, and cardiovascular conditions and creating urgent demand for faster, AI-assisted early detection systems.
Why Buy This Report
- Provides an in-depth analysis of the impact of Japan’s demographic shift, government digital health policy, radiologist workforce shortage, and hospital technology modernisation programs on the overall Japan Artificial Intelligence in Diagnostics Market growth trajectory through 2035.
- Delivers strategic intelligence on emerging technology trends including generative AI for diagnostic report automation, federated learning for multi-hospital data collaboration, large language model-powered clinical decision support, real-time AI pathology screening, and multimodal imaging AI platforms reshaping Japan’s diagnostics landscape.
- Assists stakeholders in evaluating competitive benchmarking, regulatory approval timelines under Japan’s accelerated AI medical device framework, investment opportunities in domestic AI diagnostics startups, and strategic partnership models between domestic technology firms and international healthcare majors.
Competitive Analysis:
The report offers the appropriate analysis of the key organisations and companies involved within the Japan Artificial Intelligence in Diagnostics Market, along with a comparative evaluation primarily based on their product offerings, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan Artificial Intelligence in Diagnostics Market
- FUJIFILM Holdings Corporation
- Canon Medical Systems Corporation (Canon Inc.)
- Toshiba Medical Systems (Canon Group)
- NEC Corporation
- Hitachi, Ltd.
- Siemens Healthineers AG
- GE HealthCare Technologies Inc.
- Koninklijke Philips N.V.
- IBM Corporation (IBM Watson Health)
- Google LLC (Google Health)
Recent Developments:
- In November 2025, Canon Medical Systems launched an upgraded AI-integrated CT scanner incorporating high-resolution imaging and reduced radiation dose technology, backed by JPY 48 million in domestic production and R&D investment, targeting hospitals and diagnostic imaging centres across Japan.
- In September 2025, Google launched a new AI healthcare platform tailored specifically for Japanese healthcare providers, designed to facilitate secure clinical data sharing, improve patient management workflows, and accelerate AI diagnostics integration across hospital networks throughout Japan.
Market Segmentation:
Japan Artificial Intelligence in Diagnostics Market, By Component
- AI Software & Deep Learning Platforms
- Hardware (AI-Integrated Imaging Devices & Processors)
- Services (Consulting, Integration & Managed Diagnostics)
Japan Artificial Intelligence in Diagnostics Market, By Diagnosis Type
- Radiology & Medical Imaging
- Oncology & Cancer Diagnostics
- Cardiology
- Neurology
- Pathology & Others
Japan Artificial Intelligence in Diagnostics Market, By End User
- Hospitals & Academic Medical Centres
- Diagnostic Imaging Centres & Radiology Clinics
- Pharmaceutical & Biotechnology Research Firms
- Contract Research Organisations (CROs)
- Government & Public Health Institutions
Expert Views:
The Japan Artificial Intelligence in Diagnostics Market is at an inflection point, with demographic pressure from one of the world’s most aged populations converging with a well-established national commitment to technological innovation in healthcare. As Japan’s radiologist and specialist workforce shortage deepens, AI diagnostic tools will shift from being supplementary aids to essential infrastructure across hospital networks. Leading domestic players such as FUJIFILM, Canon Medical, Hitachi, and NEC Corporation hold strong ground through proprietary imaging platforms and deep institutional relationships, while global entrants including Siemens Healthineers, Google Health, and IBM are intensifying their footprint through partnerships and platform acquisitions. The acceleration of Japan’s regulatory approval process for AI-based medical devices and the government’s active promotion of digital health transformation will continue to unlock significant adoption growth across oncology, cardiology, and radiology diagnostics, positioning Japan as a leading Asia-Pacific hub for clinical AI innovation through 2035.
Author: Aditi and Govind By Spherical Insights and Consulting